List of Excipients in Branded Drug VYVGART

« Back to Dashboard

VYVGART Excipient Strategy, Formulation Patents, Commercial Opportunities, and Generic Risk

Last updated: September 4, 2026

VYVGART is a biologic franchise built around efgartigimod alfa, an engineered antibody fragment that reduces pathogenic IgG through neonatal Fc receptor modulation. Its excipient strategy differs by presentation: intravenous VYVGART uses a conventional protein-injection platform, while VYVGART HYTRULO combines efgartigimod alfa with recombinant human hyaluronidase for subcutaneous delivery. The commercial value lies less in the individual excipients than in their role in protein stability, injection tolerability, device compatibility, manufacturing control, and lifecycle differentiation.

The franchise has two FDA-approved presentations:

Product	Active ingredients	Route	Key FDA indication
VYVGART	Efgartigimod alfa	Intravenous infusion	Generalized myasthenia gravis in adults who are anti-AChR antibody positive
VYVGART HYTRULO	Efgartigimod alfa plus hyaluronidase-qvfc	Subcutaneous injection	Generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in adults

FDA approved intravenous VYVGART in December 2021, HYTRULO for generalized myasthenia gravis in June 2023, and HYTRULO for chronic inflammatory demyelinating polyneuropathy in June 2024. [1-3]

What excipients are used in VYVGART and VYVGART HYTRULO?

VYVGART uses histidine buffering, arginine hydrochloride for formulation support, and polysorbate 80 as a surfactant. HYTRULO uses a related protein formulation but adds methionine and sodium chloride to support the subcutaneous product’s stability and tonicity profile.

VYVGART intravenous formulation

The VYVGART injection contains:

• Efgartigimod alfa
• L-histidine
• L-histidine hydrochloride monohydrate
• Arginine hydrochloride
• Polysorbate 80
• Water for injection

The product is supplied as a concentrated solution for dilution before intravenous administration. The excipient system is designed to control pH, limit protein adsorption and aggregation, and maintain product quality during storage and infusion preparation. [1]

VYVGART HYTRULO subcutaneous formulation

VYVGART HYTRULO contains:

• Efgartigimod alfa
• Recombinant human hyaluronidase PH20, identified in the product as hyaluronidase-qvfc
• L-histidine
• L-histidine hydrochloride monohydrate
• Methionine
• Polysorbate 80
• Sodium chloride
• Water for injection

Hyaluronidase temporarily modifies the extracellular matrix at the injection site, allowing a large-volume biologic dose to be administered subcutaneously. This excipient is therefore a delivery-enabling active component rather than a conventional formulation additive. [2]

How does the VYVGART excipient strategy support product performance?

The formulation strategy addresses four technical constraints: antibody-fragment stability, interfacial stress, injection-site tolerability, and subcutaneous delivery volume.

Histidine buffer

Histidine and histidine hydrochloride provide pH control. Histidine is widely used in monoclonal-antibody and antibody-fragment formulations because it can maintain a mildly acidic environment while limiting pH-driven aggregation and chemical degradation.

For VYVGART, the buffer system supports a ready-to-dilute intravenous product. For HYTRULO, it must also remain compatible with subcutaneous administration and hyaluronidase activity.

Arginine hydrochloride

Arginine hydrochloride can reduce protein-protein interactions and aggregation. It is frequently used in high-concentration protein formulations and in products exposed to concentration, freeze-thaw, or agitation stress.

In an intravenous product, arginine also helps manage the physical behavior of the concentrated solution before dilution. Its presence creates a formulation distinction between the IV and subcutaneous products.

Polysorbate 80

Polysorbate 80 protects the protein from adsorption to container surfaces, tubing, infusion bags, and other interfaces. This is important for a product that moves through preparation and infusion equipment before administration.

The commercial and manufacturing risk is polysorbate degradation. Oxidation and hydrolysis can generate subvisible particles, free fatty acids, or other degradation products. These risks make control of raw-material quality, peroxide levels, storage conditions, and container closure systems commercially relevant.

Methionine

Methionine is used in HYTRULO but is not identified as an excipient in the same way in the IV VYVGART formulation. It can function as an antioxidant scavenger and may reduce oxidative modification of the protein.

Its inclusion indicates that the subcutaneous formulation has a distinct degradation-risk profile. The product must remain stable at higher local concentration and during administration through a delivery device, conditions that are different from diluted IV infusion.

Sodium chloride

Sodium chloride supports osmolality and injection-site tolerability. In HYTRULO, sodium chloride is relevant to subcutaneous administration, where tonicity and injection volume can affect pain, tolerability, and adherence.

Hyaluronidase-qvfc

Hyaluronidase is the central excipient-driven differentiator in HYTRULO. It creates a temporary permeability window in subcutaneous tissue, allowing administration of a biologic dose that would otherwise require intravenous infusion or a substantially longer injection.

The excipient creates a separate manufacturing and quality-control burden. Commercial supply requires a qualified recombinant hyaluronidase source, validated potency assays, control of host-cell impurities, and compatibility with the efgartigimod formulation.

What commercial opportunities exist in VYVGART excipients?

The largest opportunities are in specialized biologic excipients and delivery-enabling systems, not commodity buffer salts.

High-value excipient opportunities

Opportunity	Commercial rationale	Primary buyer
Low-peroxide polysorbate 80	Reduces oxidation and particle risk in protein products	Biologic manufacturers and CDMOs
Protein-grade histidine systems	Supports pH control and aggregation management	Formulation developers
Methionine and antioxidant systems	Addresses oxidative degradation in concentrated biologics	Injectable product developers
Recombinant hyaluronidase	Enables subcutaneous delivery of large biologic doses	Drug sponsors and device partners
Low-extractables containers	Limits interaction with surfactant-containing biologics	Primary packaging suppliers
Ready-to-use delivery systems	Reduces preparation burden and administration time	Specialty pharmaceutical companies
Excipient analytics	Detects polysorbate degradation and particles	Quality-control laboratories and CDMOs

The most defensible opportunity is recombinant hyaluronidase. Its value is tied to route-of-administration conversion, not merely formulation optimization. A successful hyaluronidase platform can be applied to multiple large-volume biologics, although intellectual-property, supply, and regulatory barriers are significant.

Excipient suppliers also can capture value through analytical packages that measure polysorbate concentration, peroxide content, hydrolysis products, protein aggregation, subvisible particles, and container interaction. These services become more important as biologics move from infusion centers to home or office-based injection.

How does VYVGART compare with competing biologic formulations?

VYVGART competes with therapies that use different delivery and formulation strategies.

Product	Active modality	Route	Delivery model	Formulation opportunity
VYVGART	FcRn antagonist antibody fragment	IV	Infusion-center administration	Stability, dilution, infusion compatibility
VYVGART HYTRULO	FcRn antagonist plus hyaluronidase	SC	Shorter subcutaneous administration	Hyaluronidase, injection tolerability, device performance
Vyvgart competitors such as RYSTIGGO	FcRn-targeting antibody	SC	Prefilled or injection-based delivery	High-concentration protein stability and device compatibility
Soliris and Ultomiris	Complement inhibitors	IV or SC depending on product	Infusion or subcutaneous delivery	Long-acting dosing and route conversion
IVIG products	Polyclonal IgG mixtures	IV or SC	Infusion or facilitated SC delivery	Stabilization, volume reduction, and hyaluronidase systems

HYTRULO’s strategic advantage is the combination of FcRn pathway activity and a subcutaneous delivery platform. Its commercial disadvantage is the complexity of maintaining two biologically active components in one product.

What patents protect VYVGART and its formulation?

VYVGART is a biologic, so its exclusivity profile is divided among regulatory exclusivity, composition-of-matter rights, antibody-fragment engineering claims, formulation claims, manufacturing claims, and method-of-use patents.

The FDA Orange Book does not generally list biologic products in the same manner as approved small-molecule drugs. VYVGART’s core biologic and patent information is more appropriately reviewed through FDA biologics records, the Purple Book framework, USPTO records, and publicly available patent litigation databases. [4-6]

Potential protection categories include:

• Efgartigimod amino-acid sequence and engineered FcRn-binding properties
• Antibody-fragment formats and FcRn antagonism
• Use in generalized myasthenia gravis
• Use in chronic inflammatory demyelinating polyneuropathy
• Combination with recombinant hyaluronidase
• Subcutaneous administration methods
• Stabilized protein formulations
• Container, device, and administration systems
• Manufacturing and purification processes

The formulation strategy may provide meaningful lifecycle protection even where the active molecule has earlier composition-of-matter patents. Formulation patents are strongest when they claim a defined combination of concentrations, pH, excipient ratios, stability performance, or delivery conditions that are difficult to design around.

When does VYVGART lose exclusivity?

VYVGART does not have one single exclusivity date. The relevant dates depend on the patent family, regulatory designation, indication, and product presentation.

FDA biologic exclusivity generally provides 12 years of reference-product exclusivity for a licensed biologic, subject to the applicable statutory framework. VYVGART’s first U.S. licensure occurred in 2021, creating a reference-product exclusivity period that extends beyond the earliest approval date for many small-molecule generic products. [7]

The practical entry timeline will be determined by:

1. Expiration of valid composition and use patents.
2. Expiration of formulation or delivery patents.
3. Availability of a biosimilar pathway.
4. FDA approval of a competing biologic.
5. Patent litigation and any settlement terms.
6. Commercial feasibility of manufacturing efgartigimod or a comparable FcRn biologic.

The IV product and HYTRULO may have different risk profiles. A biosimilar to efgartigimod alfa would not automatically reproduce the commercial or legal position of a product containing hyaluronidase-qvfc. A competing sponsor could pursue an IV biosimilar, a separate subcutaneous formulation, or a different hyaluronidase combination.

Are there Paragraph IV challenges to VYVGART?

Paragraph IV litigation is a Hatch-Waxman mechanism for small-molecule drugs. VYVGART is a biologic and is not ordinarily challenged through a conventional Abbreviated New Drug Application with a Paragraph IV certification.

The relevant competitive pathway is a biosimilar application under the Public Health Service Act. Biosimilar applicants can face patent-disclosure, notice, and litigation procedures under the Biologics Price Competition and Innovation Act. [7]

As a result, the absence of a traditional Paragraph IV filing does not mean the product lacks patent risk. It means the risk must be analyzed through biologic patent litigation, biosimilar applications, declaratory actions, and potential licensing or settlement agreements.

What FDA regulatory issues affect VYVGART excipients?

Excipient changes can trigger comparability work, stability studies, process validation, and potentially regulatory supplements. The risk depends on the change.

A change from one grade of polysorbate 80 to another may require comparative characterization, degradation testing, and container-closure assessment. A change in histidine concentration can affect pH, aggregation, osmolality, and potency. A change in hyaluronidase source can require extensive analytical and functional comparability because hyaluronidase is an active component of HYTRULO.

The most sensitive controls include:

• Protein aggregation and fragmentation
• Polysorbate oxidation and hydrolysis
• Subvisible and visible particles
• Hyaluronidase potency
• Host-cell protein and DNA impurities
• Endotoxin and bioburden
• Container-closure integrity
• Injection-site tolerability
• Device compatibility
• In-use stability after preparation

What generic and biosimilar launch scenarios exist?

Three scenarios are commercially plausible.

Scenario 1: IV biosimilar entry

A competitor targets efgartigimod alfa through an IV biosimilar application. The principal barriers are analytical similarity, clinical pharmacology, immunogenicity, manufacturing scale, and patent litigation.

Scenario 2: Subcutaneous follow-on product

A competitor develops a separate subcutaneous FcRn inhibitor or a different hyaluronidase combination. This route can compete with HYTRULO without being a direct formulation copy.

Scenario 3: Therapeutic substitution

A competing FcRn antagonist or immunoglobulin-reduction therapy gains preferred formulary status. In this scenario, the commercial threat arises from clinical positioning and payer economics rather than a direct biosimilar launch.

The highest-value protection for argenx is therefore likely to combine molecule claims, indication claims, subcutaneous delivery claims, manufacturing controls, and commercial switching advantages.

What is the commercial outlook for VYVGART excipient suppliers?

VYVGART has created demand across the specialty biologics supply chain. The most attractive segments are:

• Recombinant hyaluronidase supply
• Low-oxidation surfactants
• Protein formulation screening
• Subcutaneous delivery devices
• Prefilled syringe and autoinjector systems
• Particle and degradation analytics
• Cold-chain and stability services
• CDMO manufacturing for complex biologic combinations

Argenx reported rapid growth in VYVGART product sales following the 2021 launch, with the franchise expanding from generalized myasthenia gravis into chronic inflammatory demyelinating polyneuropathy. [8] The HYTRULO presentation can increase treatment-site flexibility and reduce infusion-center dependence, which expands the addressable commercial model.

The principal risks are concentration around one franchise, dependence on qualified hyaluronidase supply, manufacturing complexity, competing FcRn therapies, and payer pressure as the class expands.

Key Takeaways

• VYVGART uses histidine, arginine hydrochloride, polysorbate 80, and water for injection in its IV presentation.
• HYTRULO adds methionine, sodium chloride, and recombinant hyaluronidase-qvfc to support subcutaneous delivery.
• Hyaluronidase is the most strategically important excipient in the franchise because it enables route conversion from IV infusion to subcutaneous administration.
• Polysorbate quality, protein aggregation, particle formation, and container compatibility are central technical risks.
• VYVGART is regulated as a biologic, so biosimilar litigation and BPCIA procedures are more relevant than conventional Paragraph IV challenges.
• Formulation, delivery, manufacturing, and method-of-use patents can extend commercial protection beyond the core molecule.
• The strongest supplier opportunities are recombinant hyaluronidase, biologic-grade surfactants, analytical services, and subcutaneous delivery systems.

FAQs

What is the most important excipient in VYVGART HYTRULO?

Recombinant human hyaluronidase PH20, identified as hyaluronidase-qvfc, is the most important because it enables subcutaneous administration of the efgartigimod dose.

Does VYVGART contain polyethylene glycol?

The FDA labeling for VYVGART identifies polysorbate 80 rather than polyethylene glycol as the principal surfactant excipient. [1]

Can a biosimilar copy the HYTRULO formulation?

A biosimilar applicant can pursue a product with the same reference biologic and delivery characteristics, but it must address formulation, hyaluronidase compatibility, analytical similarity, patent rights, and FDA requirements.

Why is polysorbate 80 a risk in biologic manufacturing?

Polysorbate 80 can undergo oxidation and hydrolysis, potentially producing particles and affecting protein stability. Raw-material quality and degradation monitoring are therefore important.

Is VYVGART listed in the Orange Book?

VYVGART is a biologic. Its principal regulatory and patent analysis is conducted through biologic approval records, Purple Book-related materials, USPTO records, and applicable biologic patent litigation, rather than the conventional Orange Book framework.

References

1. U.S. Food and Drug Administration. (2024). VYVGART (efgartigimod alfa-fcab) injection, prescribing information.
2. U.S. Food and Drug Administration. (2024). VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) injection, prescribing information.
3. U.S. Food and Drug Administration. (2024). FDA approves treatment for chronic inflammatory demyelinating polyneuropathy.
4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
5. U.S. Patent and Trademark Office. (2024). Patent Center.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
7. Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
8. argenx SE. (2024). Annual report and financial results.